The Melanoma Research Program is composed of 24 investigators (17 Full and 7 Associate members) from 10 Departments. The Program has 3 major scientific objectives: 1) Develop new prognostic models for patients with primary melanoma that integrate molecular biomarkers with clinical variables;2) Discover the biologic heterogeneity of melanoma with emphasis on molecular alterations that are associated with disease progression and drug resistance;and 3) Develop and integrate emerging novel immunotherapeutic approaches with chemotherapeutic and biological therapies in the treatment of melanoma. Drs. Nina Bhardwaj and Iman Osman are the Co-Leaders for this Program. Total funding increased from $2,739,004 to $4,841,572 since the last competitive application. Membership has increased from 19 to 24 members. Publications for the period total 156, of which 23.7% are intra-programmatic, 20.5% are inter-programmatic, and 12.2% are both intra- and inter-programmatic collaborations.
The incidence of melanoma and deaths due to melanoma continue to increase, but at present there are no successful methods for treatment of advanced disease. The NYUCI Melanonta Program, proposes research that aims to improve detection and therapies that will potentially reduce the number of deaths from melanoma.
Showing the most recent 10 out of 1170 publications
